A Study of LY2969822 in Healthy Participants

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

99 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-12-31

Study Completion Date

2015-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate how safe LY2969822 (study drug) is and whether it causes any side effects. The study will also measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of the study drug. This is the first time that this study drug is being given to participants. This study is for research purposes only and is not intended to treat any medical condition.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Safety Study of LY3493269 Given as a Single Injection in Healthy Participants

NCT04178733

Healthy

COMPLETED PHASE1

A Study of LY3053102 in Healthy Participants

NCT01736241

Healthy Volunteers

COMPLETED PHASE1

A Study of LY3873862 in Healthy Participants

NCT05492201

Healthy

COMPLETED PHASE1

A Study of LY2775240 in Healthy Participants

NCT02963779

Healthy

COMPLETED PHASE1

A Safety Study of LY3372689 in Healthy Participants

NCT04106206

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants in Part A will complete three study periods, which together will last about 40 days. Participants in Parts B and C will complete one study period which will last about 17 days, but the total study time is about 40 days. Each participant may only enroll in one part. Screening is required within 28 days prior to the start of the study for all participants.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY2969822 (Part A)

Single dose of LY2969822 administered orally in 2 of 3 study periods.

Group Type EXPERIMENTAL

LY2969822

Intervention Type DRUG

Capsules administered orally

Placebo (Part A)

Single dose of placebo administered orally in 1 of 3 study periods.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Capsules administered orally

LY2969822 (Part B)

LY2969822 administered orally for 14 days.

Group Type EXPERIMENTAL

LY2969822

Intervention Type DRUG

Capsules administered orally

Placebo (Part B)

Placebo administered orally for 14 days.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Capsules administered orally

LY2969822 (Part C)

LY2969822 administered orally for 14 days.

Group Type EXPERIMENTAL

LY2969822

Intervention Type DRUG

Capsules administered orally

Placebo (Part C)

Placebo administered orally for 14 days.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Capsules administered orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY2969822

Capsules administered orally

Intervention Type DRUG

Placebo

Capsules administered orally

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male participants must agree to use a reliable method of birth control in addition to having their partner use another method for the duration of the study and for 3 months after the last dose of LY2969822
* Female participants must not be of child-bearing potential
* Participants have a body mass index (BMI) of 18.5 to 29.9 kilogram per meter square (kg/m\^2), inclusive, at screening

Exclusion Criteria

* Have participated, within the last 30 days (prior to first dose in this study), in a clinical trial involving an investigational product
* Have a significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
* Intended use of over-the-counter medication within 14 days prior to dosing or during the study with the exception of vitamins and mineral supplements or occasional paracetamol or acetaminophen
* Intended use of herbal supplements or prescription medications, other than stable doses of thyroid or estrogen hormone replacement, within 14 days prior to dosing or during the study

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes